<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01175798</url>
  </required_header>
  <id_info>
    <org_study_id>09-2275</org_study_id>
    <nct_id>NCT01175798</nct_id>
  </id_info>
  <brief_title>Impact of Vitamin D Repletion in Hemodialysis Patients</brief_title>
  <official_title>Immunologic Impact of Vitamin D Repletion in Hemodialysis Patients: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mehrotra, Anita, M.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Kidney Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>American Heart Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Mehrotra, Anita, M.D.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dialysis patients often suffer from defects in their immune system (that part of the body
      which fights infection). Evidence suggests that Vitamin D deficiency may have a negative
      effect on immunity, and many dialysis patients are deficient in Vitamin D. We believe that by
      giving Vitamin D to dialysis patients who are deficient, we may help improve their immune
      system. This study will test that idea.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Innate and adaptive immunity are commonly impaired in patients with end stage renal disease
      (ESRD) on dialysis. The myriad of immune defects in these patients, often attributed to
      uremia, may account for their high risk of bacterial infection and suboptimal responses to
      vaccination. The mechanisms underlying these abnormalities in immune function remain elusive,
      but emerging evidence indicates that 25OH-Vitamin D exerts potent and complex control over
      innate and adaptive immunity. Vitamin D deficiency is common in dialysis patients, and the
      immune effects associated with 25OH-Vit D deficiency overlap with those found in many
      dialysis patients. The kidney is the dominant site of 1-alpha-hydroxylase activity required
      for producing active 1,25OH-Vit D; however, immune cells also express the 1-alpha-hydroxylase
      enzyme. Evidence indicates the effects of Vitamin D on modulating immunity require conversion
      of 25OH-Vit D to 1,25OH-Vit D within the immune cells (rather than via circulating 1,25OH-Vit
      D). As a consequence, total body deficiency of 25OH-Vit D can impact immune function despite
      ongoing therapy with active 1,25OH-Vit D (which most dialysis patients are receiving). Our
      preliminary data confirm the high prevalence of 25OH-Vit D deficiency in dialysis patients
      and show that Th1 T cell alloimmunity is stronger in patients deficient in 25OH-Vit D,
      supporting the hypothesis that Vit D deficiency has important immunological consequences.
      Based on the published literature and our preliminary data, we hypothesize that repletion of
      25OH-Vit D enhances immunity in dialysis patients. To test this hypothesis, we propose a
      randomized controlled trial of oral 25OH-Vit D repletion in this patient population. One
      hundred fifty 25OH-Vit D deficient study subjects will be randomized to either treatment with
      50,000 IU oral 25OH-Vit D weekly or no treatment (standard of care). The primary outcome of
      change in 25OH-Vit D level will be measured at 6 weeks, 3 months, 6 months, and 12 months.
      Secondary outcomes to be measured include change in peripheral blood mononuclear cell (PBMC)
      profile by flow cytometry at 6 and 12 months, change in ELISPOT-based panel of reactive T
      cell (PRT) readout at 6 and 12 months, change in PMBC cytokine production in response to
      toll-like-receptor stimulation at 6 and 12 months, and response to influenza vaccination.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in 25OH-Vitamin D Level</measure>
    <time_frame>1 year</time_frame>
    <description>Vitamin D deficient study subjects will be randomized to either treatment with 50,000 IU oral 25OH-Vit D weekly or no treatment (standard of care). The primary outcome of change in 25OH-Vit D level will be measured at 6 weeks, 3 months, 6 months, and 12 months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Immune Parameters</measure>
    <time_frame>1 year</time_frame>
    <description>Secondary outcomes to be measured include change in peripheral blood mononuclear cell (PBMC) profile by flow cytometry at 6 and 12 months, change in ELISPOT-based panel of reactive T cell (PRT) readout at 6 and 12 months, change in PMBC cytokine production in response to toll-like-receptor stimulation at 6 and 12 months, and response to influenza vaccination.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">116</enrollment>
  <condition>Vitamin D Deficiency</condition>
  <condition>End-stage Renal Disease</condition>
  <arm_group>
    <arm_group_label>No treatment (standard of care)</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients will be randomized in a 3:2 ratio to oral Vitamin D treatment, or standard of care (no repletion).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vitamin D repletion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be randomized in a 3:2 ratio to oral Vitamin D treatment, or standard of care (no repletion).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cholecalciferol</intervention_name>
    <description>50,000 IU PO weekly x 6 weeks</description>
    <arm_group_label>Vitamin D repletion</arm_group_label>
    <other_name>Vitamin D</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age &gt; 18 years

          2. Chronic hemodialysis treatments for at least 2 consecutive months

          3. 25OH-Vitamin D level &lt; 25 ng/mL (inclusion criteria for randomization)

        Exclusion Criteria:

          1. History of acute renal failure requiring dialysis with potential for renal recovery

          2. History of HIV/AIDS

          3. Inability to provide informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anita Mehrotra, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mount Sinai School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 3, 2010</study_first_submitted>
  <study_first_submitted_qc>August 3, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 5, 2010</study_first_posted>
  <results_first_submitted>September 15, 2014</results_first_submitted>
  <results_first_submitted_qc>September 15, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 22, 2014</results_first_posted>
  <last_update_submitted>September 15, 2014</last_update_submitted>
  <last_update_submitted_qc>September 15, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 22, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Icahn School of Medicine at Mount Sinai</investigator_affiliation>
    <investigator_full_name>Anita Mehrotra MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Vitamin D deficiency</keyword>
  <keyword>End-stage renal disease</keyword>
  <keyword>Immunity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
    <mesh_term>Vitamin D Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>No Treatment (Standard of Care)</title>
          <description>Patients will be randomized in a 3:2 ratio to oral Vitamin D treatment, or standard of care (no repletion).</description>
        </group>
        <group group_id="P2">
          <title>Vitamin D Repletion</title>
          <description>Patients will be randomized in a 3:2 ratio to oral Vitamin D treatment, or standard of care (no repletion).
Cholecalciferol: 50,000 IU PO weekly x 6 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="62"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>No Treatment (Standard of Care)</title>
          <description>Patients will be randomized in a 3:2 ratio to oral Vitamin D treatment, or standard of care (no repletion).</description>
        </group>
        <group group_id="B2">
          <title>Vitamin D Repletion</title>
          <description>Patients will be randomized in a 3:2 ratio to oral Vitamin D treatment, or standard of care (no repletion).
Cholecalciferol: 50,000 IU PO weekly x 6 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="34"/>
            <count group_id="B2" value="62"/>
            <count group_id="B3" value="96"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.9" spread="14.9"/>
                    <measurement group_id="B2" value="60.2" spread="14.3"/>
                    <measurement group_id="B3" value="59" spread="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>25(OH) vitamin D</title>
          <units>ng/dL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13.1" lower_limit="9.9" upper_limit="18.6"/>
                    <measurement group_id="B2" value="13.4" lower_limit="9.3" upper_limit="19.7"/>
                    <measurement group_id="B3" value="13.2" lower_limit="9.5" upper_limit="19.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in 25OH-Vitamin D Level</title>
        <description>Vitamin D deficient study subjects will be randomized to either treatment with 50,000 IU oral 25OH-Vit D weekly or no treatment (standard of care). The primary outcome of change in 25OH-Vit D level will be measured at 6 weeks, 3 months, 6 months, and 12 months.</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>No Treatment (Standard of Care)</title>
            <description>Patients will be randomized in a 3:2 ratio to oral Vitamin D treatment, or standard of care (no repletion).</description>
          </group>
          <group group_id="O2">
            <title>Vitamin D Repletion</title>
            <description>Patients will be randomized in a 3:2 ratio to oral Vitamin D treatment, or standard of care (no repletion).
Cholecalciferol: 50,000 IU PO weekly x 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in 25OH-Vitamin D Level</title>
          <description>Vitamin D deficient study subjects will be randomized to either treatment with 50,000 IU oral 25OH-Vit D weekly or no treatment (standard of care). The primary outcome of change in 25OH-Vit D level will be measured at 6 weeks, 3 months, 6 months, and 12 months.</description>
          <units>ng/dL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.8" lower_limit="9.5" upper_limit="19.5"/>
                    <measurement group_id="O2" value="40.9" lower_limit="32.2" upper_limit="45.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Immune Parameters</title>
        <description>Secondary outcomes to be measured include change in peripheral blood mononuclear cell (PBMC) profile by flow cytometry at 6 and 12 months, change in ELISPOT-based panel of reactive T cell (PRT) readout at 6 and 12 months, change in PMBC cytokine production in response to toll-like-receptor stimulation at 6 and 12 months, and response to influenza vaccination.</description>
        <time_frame>1 year</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>No Treatment (Standard of Care)</title>
          <description>Patients will be randomized in a 3:2 ratio to oral Vitamin D treatment, or standard of care (no repletion).</description>
        </group>
        <group group_id="E2">
          <title>Vitamin D Repletion</title>
          <description>Patients will be randomized in a 3:2 ratio to oral Vitamin D treatment, or standard of care (no repletion).
Cholecalciferol: 50,000 IU PO weekly x 6 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Anita Mehrotra MD</name_or_title>
      <organization>Icahn School of Medicine at Mount Sinai</organization>
      <phone>2122415153</phone>
      <email>anita.mehrotra@mssm.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

